Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18956941 | COMPOSITIONS AND METHODS FOR TREATING CANCER | November 2024 | June 2025 | Allow | 6 | 1 | 1 | No | No |
| 18783231 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | July 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18710113 | FERROPTOSIS INHIBITOR AND USE THEREFOR | May 2024 | February 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18611561 | NANOMATERIALS COMPRISING TRIOLS | March 2024 | December 2024 | Allow | 9 | 1 | 1 | No | No |
| 18606722 | SMALL MOLECULE COMPOUNDS HAVING NAPHTHYLAMINE STRUCTURE AND APPLICATION THEREOF | March 2024 | September 2024 | Allow | 7 | 1 | 1 | No | No |
| 18443136 | 4-THIAZOLIDINONE DERIVATIVES AS EGFR INHIBITORS FOR ANTI-TUMOR ACTIVITY | February 2024 | July 2024 | Allow | 5 | 0 | 1 | No | No |
| 18405638 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | January 2024 | August 2024 | Allow | 7 | 1 | 1 | No | No |
| 18393644 | PYRIMIDO[1',6':1,5]PYRAZOLO[4,3-B][1,7]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORS | December 2023 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18542368 | PYRIDO[4',3':4,5]PYRROLO[2,3-C][2,7]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORS | December 2023 | August 2024 | Allow | 8 | 0 | 1 | No | No |
| 18115020 | TERPENE-ENRICHED CANNABINOID COMPOSITION AND METHOD OF TREATMENT | February 2023 | December 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18154752 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | January 2023 | July 2024 | Abandon | 18 | 1 | 1 | No | No |
| 18050269 | COMPOSITIONS AND METHODS FOR TREATING CANCER | October 2022 | April 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18048478 | SYNERGISTIC COMPOSITION FOR VEISALGIA PREVENTION | October 2022 | December 2023 | Abandon | 13 | 1 | 0 | No | No |
| 17959751 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | October 2022 | December 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17934009 | METHODS OF TREATING FIBROTIC PATHOLOGIES | September 2022 | June 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17864095 | COMPOSITIONS AND METHODS USING CANNABINOID COMPOUNDS FOR REGULATING GASTRIC ACID SECRETION TO TREAT GASTROESOPHAGEAL REFLUX DISEASE AND RELATED CONDITIONS | July 2022 | March 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17851954 | NEUROLYTIC AGENTS AND METHODS OF USING AND IDENTIFYING SAME | June 2022 | April 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17845251 | INTOXICATION-REDUCING SUPPLEMENTAL MIXTURE | June 2022 | December 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17715276 | ENDOCANNABINOID SYSTEM-TARGETING PRODRUGS AND THERAPEUTIC USES THEREOF | April 2022 | October 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17711105 | COMPOSITIONS CONTAINING ANDROGEN RECEPTOR ANTAGONISTS | April 2022 | May 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17680995 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | February 2022 | August 2024 | Allow | 30 | 1 | 1 | No | No |
| 17668316 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | February 2022 | May 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17666197 | pH STABLE UREA COMPOSITION AND USE THEREOF | February 2022 | August 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17665493 | SYNERGISTIC COMPOSITION FOR VEISALGIA PREVENTION | February 2022 | September 2023 | Abandon | 19 | 1 | 0 | Yes | No |
| 17523002 | KP372-1-INDUCED DNA DAMAGE AS A CHEMOTHERAPEUTIC APPROACH TO TREAT CANCER | November 2021 | June 2024 | Allow | 31 | 2 | 1 | No | No |
| 17521004 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | November 2021 | March 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17519771 | Composition for increasing skin thickness | November 2021 | July 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17518952 | COMPOSITION AND METHOD FOR TREATMENT OF DIABETES | November 2021 | March 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17496921 | BACE1 INHIBITORY LIGAND MOLECULES AGAINST AMYLOID BETA-INDUCED SYNAPTIC AND MITOCHONDRIAL TOXICITIES | October 2021 | May 2024 | Allow | 31 | 2 | 1 | No | No |
| 17489255 | FULL SPECTRUM HEMP OIL COMPOSITIONS | September 2021 | September 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17487430 | ABSORPTION ENHANCER OF CINNAMIC ACID DERIVATIVE | September 2021 | July 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17437375 | FGFR4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | September 2021 | May 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17464233 | BRONCHODILATORS FOR TREATING OBSTRUCTIVE LUNG DISEASE | September 2021 | December 2024 | Allow | 39 | 4 | 0 | Yes | No |
| 17300593 | Pharmaceutical composition to destabilize abnormal methylation enzymes and use thereof | August 2021 | June 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17432279 | COMPOSITIONS PROVIDING ENHANCED ANTIBACTERIAL ACTIVITY AGAINST GRAM-POSITIVE BACTERIA AND USE THEREOF | August 2021 | May 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17429707 | INJECTABLE CLORSULON COMPOSITIONS, METHODS AND USES THEREOF | August 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17385748 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | July 2021 | March 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17383930 | COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | July 2021 | October 2024 | Allow | 39 | 3 | 1 | Yes | No |
| 17310032 | COMBINATION OF SELECTIVE ALPHA-ADRENERGIC RECEPTOR AGONIST OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF | July 2021 | March 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17371941 | CANNABIS EXTRACTS AND USES THEREOF | July 2021 | December 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17419915 | Topical Formulation for Use in Alopecia | June 2021 | January 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17417727 | CANCER TREATMENT PHARMACEUTICAL COMPOSITION CONTAINING CDK INHIBITOR | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17415813 | NOTCH INHIBITORS FOR THE TREATMENT OF VASCULAR MALFORMATIONS | June 2021 | June 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17414672 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17413689 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | June 2021 | May 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17296098 | BENZHYDRYLATED AROMATIC SURFACTANTS | May 2021 | March 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17319500 | COMPOSITIONS AND METHODS FOR SUPPRESSING MSUT2 | May 2021 | March 2025 | Abandon | 46 | 3 | 1 | No | No |
| 17290417 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | April 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17290354 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | April 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17244094 | BRIMONIDINE COMBINATIONS AND USES THEREOF | April 2021 | December 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17284011 | The use of a H3R inverse agonist for the treatment of excessive daytime sleepiness associated with parkinson's disease (PD) | April 2021 | January 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17283904 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | April 2021 | August 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17220307 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | April 2021 | June 2025 | Allow | 50 | 3 | 1 | No | No |
| 17280929 | METHODS AND COMPOSITIONS FOR REDUCING SERUM URIC ACID | March 2021 | December 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17212737 | COMPOSITIONS AND METHODS FOR TREATING CANCER | March 2021 | October 2022 | Allow | 19 | 1 | 1 | No | No |
| 17278625 | 2'-HALOGENATED-4'-THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF | March 2021 | February 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17197395 | SLEEP AID AND RELATED METHODS | March 2021 | December 2023 | Abandon | 33 | 2 | 1 | No | No |
| 17274175 | Treatment of inflammatory bowel disease and its extra intestinal manifestations | March 2021 | March 2025 | Abandon | 48 | 4 | 1 | No | No |
| 17271009 | FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | February 2021 | April 2025 | Allow | 50 | 2 | 1 | No | No |
| 17270588 | SELENOPHENOCHROMENE HYDROXAMIC ACIDS, PREPARATION AND USE AS ANGIOGENESIS INHIBITORS | February 2021 | April 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17173841 | ADMINISTRATION OF ANTIPSYCHOTICS | February 2021 | June 2024 | Allow | 40 | 4 | 1 | Yes | No |
| 17266751 | COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOAD | February 2021 | May 2025 | Allow | 51 | 4 | 1 | Yes | No |
| 17266960 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | February 2021 | April 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17265036 | COMPOSITIONS COMPRISING PROPOFOL, KETAMINE, AND ANALGESIC, AND METHODS OF USE | February 2021 | December 2022 | Abandon | 23 | 0 | 1 | No | No |
| 17260193 | INHIBITORS OF HISTONE DEACETYLASE | January 2021 | September 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17146013 | USE OF ANTIDEPRESSANT AGENTS FOR PREVENTING AND TREATING THE COVID-19 DISEASE | January 2021 | December 2023 | Abandon | 35 | 2 | 1 | No | No |
| 17258626 | COMPOUNDS FOR MYC INHIBITION | January 2021 | November 2022 | Allow | 22 | 2 | 1 | No | No |
| 17258402 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | January 2021 | April 2023 | Allow | 27 | 1 | 1 | No | No |
| 17258054 | COMBINATION THERAPY WITH MEK INHIBITOR AND CDK4/6 INHIBITOR TO TREAT PANCREATIC CANCER | January 2021 | December 2022 | Allow | 23 | 1 | 1 | No | No |
| 17255662 | PHARMACEUTICAL COMBINATION FOR USE IN AGE-RELATED AND/OR DEGENERATIVE DISEASES | December 2020 | April 2024 | Allow | 40 | 3 | 1 | No | No |
| 17254323 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE | December 2020 | June 2023 | Abandon | 29 | 2 | 1 | No | No |
| 17126380 | SYNERGISTIC ANTI-INFLAMMATORY COMPOSITIONS | December 2020 | July 2023 | Allow | 31 | 2 | 1 | No | No |
| 17253545 | METHOD OF TREATING EPILEPSY OR EPILEPTIC ENCEPHALOPATHY WITH FENFLURAMINE IN PATIENTS WITHOUT PULMONARY HYPERTENSION | December 2020 | December 2022 | Abandon | 24 | 1 | 0 | No | No |
| 17120681 | DEUTERATED CFTR POTENTIATORS | December 2020 | February 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17119661 | METHODS OF TREATING CANCER | December 2020 | February 2024 | Allow | 38 | 2 | 0 | No | Yes |
| 16973514 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | December 2020 | November 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17112887 | MASP-2 INHIBITORS AND METHODS OF USE | December 2020 | January 2023 | Allow | 25 | 2 | 1 | No | No |
| 16972288 | TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION FOR GLIOMA | December 2020 | March 2023 | Abandon | 28 | 2 | 0 | Yes | No |
| 17059754 | Novel Biphenyl Derivative Compound and Use Thereof | November 2020 | November 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 17105087 | OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | November 2020 | May 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17058187 | ION CHANNEL MODULATORS | November 2020 | August 2023 | Allow | 33 | 0 | 0 | No | No |
| 17057247 | Methods of Treating Renal Disease Associated With Chronic Kidney Disease Such as Alport Syndrome | November 2020 | July 2024 | Abandon | 44 | 3 | 0 | No | No |
| 15733732 | Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination | October 2020 | July 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 17021438 | COMPOUNDS USEFUL AS NEAR-INFRARED FLUORESCENT PROBES SELECTIVELY BINDING TO TAU AGGREGATES AND METHOD OF PREPARING THE SAME | September 2020 | March 2024 | Allow | 42 | 4 | 1 | No | No |
| 16977318 | GALECTINS CONTROL MTOR IN RESPONSE TO ENDOMEMBRANE DAMAGE AND PROVIDE A MECHANISM AND TARGET FOR THE TREATMENT OF AUTOPHAGY-RELATED DISEASES | September 2020 | May 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16975865 | EPILEPSY TREATMENT AGENT | August 2020 | February 2023 | Allow | 30 | 2 | 0 | No | No |
| 16975439 | HEMATOPOIESIS-ENHANCING AGENT | August 2020 | October 2022 | Allow | 26 | 1 | 1 | No | No |
| 16970879 | Targeting Lipid Metabolism and Free Fatty Acid (FFA) Oxidation to Treat Diseases Mediated by Resident Memory T Cells (TRM) | August 2020 | November 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16992674 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | August 2020 | September 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 16967401 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | August 2020 | April 2025 | Allow | 56 | 4 | 1 | No | No |
| 16965122 | METHODS OF TREATING FIBROTIC PATHOLOGIES | July 2020 | October 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16963107 | Langerin+ Cell Targeting | July 2020 | October 2024 | Allow | 51 | 1 | 1 | Yes | No |
| 16961784 | ORAL SOLUTIONS COMPRISING LISDEXAMFETAMINE SALTS | July 2020 | October 2022 | Allow | 27 | 1 | 1 | No | No |
| 16961201 | PHARMACEUTICAL COMPOSITIONS COMPRISING DICARBOXYLIC ACIDS AND THEIR THERAPEUTIC APPLICATIONS | July 2020 | January 2023 | Abandon | 31 | 1 | 1 | No | No |
| 16960226 | COMPOSITION CONTAINING SUMO INHIBITOR AND APPLICATION | July 2020 | October 2022 | Allow | 27 | 1 | 1 | No | No |
| 16913834 | COMPOUND AND METHOD FOR TREATING DISEASES AND DISORDERS | June 2020 | December 2022 | Allow | 30 | 1 | 1 | No | No |
| 16898889 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | June 2020 | August 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16897272 | USE OF HYDROXYTYROSOL ACETATE IN IMPROVING FUNCTION OF AORTIC ENDOTHELIAL CELL | June 2020 | January 2023 | Abandon | 31 | 1 | 1 | No | No |
| 16888778 | Treating Cancer with Drug Combinations | May 2020 | February 2023 | Abandon | 33 | 1 | 1 | No | No |
| 16762000 | SULFONAMIDE CARBOXAMIDE COMPOUNDS | May 2020 | September 2024 | Allow | 53 | 4 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUTTER, GILLIAN A.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HUTTER, GILLIAN A works in Art Unit 1625 and has examined 104 patent applications in our dataset. With an allowance rate of 47.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner HUTTER, GILLIAN A's allowance rate of 47.1% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HUTTER, GILLIAN A receive 1.43 office actions before reaching final disposition. This places the examiner in the 32% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HUTTER, GILLIAN A is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +60.3% benefit to allowance rate for applications examined by HUTTER, GILLIAN A. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 36.4% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 47.1% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.